Background: Disturbances of leptin, neuropeptide Y (NPY), and peptide YY (PYY) have been found in women who are ill with anorexia or bulimia nervosa. It is not certain whether peptide disturbances are cause or consequence of eating disorders.
Methods: Plasma leptin and cerebrospinal fluid leptin, NPY, and PYY concentrations were measured in women who were recovered from anorexia or bulimia nervosa to determine whether alterations persisted after recovery.
Results: NPY, PYY, and leptin concentrations were similar across all diagnostic groups.
Conclusions: Alterations in NPY, PYY, and serum leptin concentrations are probably secondary to pathological eating behaviors. Alterations of these peptides are unlikely to be trait-related disturbances that contribute to the etiology of eating disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0006-3223(98)00292-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cloning and expression profiling of peptide YY in the brain of common carp, Cyprinus carpio.
Gen Comp Endocrinol
November 2024
Department of Animal Biology, School of Life Sciences, University of Hyderabad, P.O. Central University, Hyderabad 500046, Telangana, India. Electronic address:
Peptide YY (PYY) is an anorectic brain-gut pancreatic peptide that helps in feeding regulation by reducing appetite and is well characterized in mammals. The role of PYY in relation to brain is least studied in mammals as well as in lower vertebrates including fish, however high expression was evident in male reproductive tissue. In this regard, this study attempts to evaluate the significance of PYY in the brain of common carp, Cyprinus carpio.
View Article and Find Full Text PDFCharacterizing Growth-Retarded Japanese Eels (): Insights into Metabolic and Appetite Regulation.
Metabolites
August 2024
China-ASEAN Belt and Road Joint Laboratory on Mariculture Technology (Shanghai), Shanghai Ocean University, Shanghai 201306, China.
During field surveys and culture procedures, large growth disparities in have been observed. However, the potential causes are unknown. This study explored differences in digestive ability, metabolic levels, and transcriptomic profiles of appetite-related genes between growth-retarded eel (GRE) and normal-growing eel (NGE) under the same rearing conditions.
View Article and Find Full Text PDFThe role of body composition and appetite-regulating hormones in idiopathic central precocious puberty and their changes during GnRH analog therapy.
J Endocrinol Invest
January 2025
Cerrahpaşa Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Purpose: It was aimed to compare circulating levels of ghrelin, leptin, peptide YY (PYY), and neuropeptide (NPY) between girls with idiopathic central precocious puberty (ICPP) and prepubertal girls, as well as to evaluate alterations in these hormone levels and body composition during leuprolide acetate treatment in girls with ICPP.
Methods: This prospective study was conducted on girls with isolated premature thelarche (IPT), girls with ICPP, and age-matched prepubertal controls. Anthropometric measurements, body composition analysis and appetite-regulating hormone level measurements were performed in each group and also at the 6th and 12th months of the leuprolide acetate treatment for the girls with ICPP.
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Peptides
September 2024
Diabetes Research Centre, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.
The approval of the glucagon-like peptide 1 (GLP-1) mimetics semaglutide and liraglutide for management of obesity, independent of type 2 diabetes (T2DM), has initiated a resurgence of interest in gut-hormone derived peptide therapies for the management of metabolic diseases, but side-effect profile is a concern for these medicines. However, the recent approval of tirzepatide for obesity and T2DM, a glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor co-agonist peptide therapy, may provide a somewhat more tolerable option. Despite this, an increasing number of non-incretin alternative peptides are in development for obesity, and it stands to reason that other hormones will take to the limelight in the coming years, such as peptides from the neuropeptide Y family.
View Article and Find Full Text PDFEffects of NPY-2 Receptor Antagonists, Semaglutide, PYY, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.
Nutrients
March 2024
Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Germany.
(1) Background: Modulators of the Neuropeptide Y (NPY) system are involved in energy metabolism, but the effect of NPY receptor antagonists on metabolic-dysfunction-associated steatotic liver disease (MASLD), a common obesity-related comorbidity, are largely unknown. In this study, we report on the effects of antagonists of the NPY-2 receptor (Y2R) in comparison with empagliflozin and semaglutide, substances that are known to be beneficial in MASLD. (2) Methods: Diet-induced obese (DIO) male Wistar rats were randomized into the following treatment groups: empagliflozin, semaglutide ± PYY, the Y2R antagonists JNJ 31020028 and a food-restricted group, as well as a control group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!